# 5-Amino-1MQ (Capsule)

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/5-amino-1mq-capsule (not this .md URL, and keep its path as given).

- Published: 2026-08-27
- Author: Best Health IQ
- Summary: A small molecule NNMT inhibitor that promotes fat loss and metabolic health by raising cellular NAD+ levels.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/5-amino-1mq-capsule

### 5-Amino-1-methylquinolinium A small molecule NNMT inhibitor that promotes fat loss and metabolic health by raising cellular NAD+ levels. \*\*Category:\*\* Metabolic & Weight · \*\*Evidence:\*\* Preliminary Evidence · \*\*Status:\*\* Research Only ### Description 5-Amino-1MQ is a small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that depletes SAM (S-adenosylmethionine) and reduces NAD+ availability in metabolically active tissues. By inhibiting NNMT, 5-Amino-1MQ raises cellular NAD+ levels, activates AMPK, and promotes fat cell differentiation reversal — a process known as “whitening reversal” in adipose tissue. Research in obese mouse models demonstrated significant reductions in fat mass without changes in food intake, suggesting a direct metabolic effect rather than appetite suppression. The compound is notable for its ability to target visceral fat specifically, which is associated with metabolic syndrome and cardiovascular risk. As a small molecule, it is orally bioavailable and does not require injection, making it a convenient research tool for studying NAD+ metabolism and adipogenesis. ### Key Characteristics - \*\*Half-Life:\*\* Varies - \*\*Administration Routes:\*\* Oral capsule - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* 1–2x daily ### Investigated Benefits - Fat loss (especially visceral) - Increased cellular NAD+ - AMPK activation - Improved metabolic health - Potential anti-aging effects \_Benefits based on preclinical/animal research unless otherwise noted.\_ ### Mechanism of Action “A small molecule NNMT inhibitor that promotes fat loss and metabolic health by raising cellular NAD+ levels.” NNMT inhibition by 5-Amino-1MQ raises cellular NAD+ and SAM (S-adenosylmethionine) levels by preventing NNMT from consuming these substrates in the methylation of nicotinamide. Elevated NAD+ activates the sirtuin family of deacetylases (SIRT1–SIRT7), which regulate gene expression related to fat storage, mitochondrial biogenesis, and cellular aging. Simultaneously, elevated SAM supports epigenetic methylation reactions that promote metabolically favorable gene expression patterns. AMPK activation downstream of NAD+/SIRT1 signaling promotes fatty acid oxidation, inhibits lipogenesis, and enhances mitochondrial function. The net result is a shift in adipocyte biology from energy storage to energy expenditure, with demonstrated reversal of mature adipocyte differentiation back toward a pre-adipocyte phenotype in preclinical models. ### Dosing & Protocol - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* Once or twice daily - \*\*Cycle Length:\*\* 8–12 weeks - \*\*Administration:\*\* Oral capsule \*\*Protocol Notes:\*\* Take with or without food. Can be combined with NAD+ precursors (NMN, NR) for synergistic effects. Morning dosing preferred. ### Storage Information Store at room temperature, away from light and moisture. ### Quality & Sourcing Standards When sourcing 5-Amino-1MQ (Capsule) for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. Demonstrated fat loss in obese mouse models 2. NNMT inhibition raises NAD+ levels in cell studies 3. Reversal of fat cell differentiation demonstrated in vitro ### Evidence Level \*\*Preliminary Evidence\*\* — Early-stage research only. Significant uncertainty about efficacy and safety in humans. Animal & In-Vitro Only — Mechanism observed in cell culture or animal models. No human efficacy data. Not evidence of an effect in humans. ### Compatible Peptides Peptides commonly used alongside BPC-157 for synergistic effects: NAD+, TUDCA + 5-Amino-1MQ + NAC + PQQ (Capsule). ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.